OCX Oncocyte

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 11-12, 2025, Snowbird, Utah

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.

Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

Event: BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025

Dates: February 11-12, 2025

Location: Snowbird, Utah, USA

About Oncocyte

Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit . For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - VitaGraft Liver™ -

GraftAssure™ -

DetermaIO™ - DetermaCNI™ -

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:

Jeff Ramson

PCG Advisory

(646) 863-6893



EN
11/02/2025

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection T...

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE, Tenn., June 23, 20...

June 23, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Mo...

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has anno...

June 17, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the co...

May 19, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte Reports Q1 2025 Results and Business Progress Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter ...

May 12, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: . An archived replay will be available after the c...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch